02-25-05 07:04 PM EST
30-47 % (!) der Patienten weisen nach 24 Wochen Behandlung keine (!) nachweisbaren Viren mehr auf!
BOSTON -(Dow Jones)- Johnson & Johnson's (JNJ) Tibotec Pharmaceuticals Ltd. unit said its TMC114 protease inhibitor demonstrated efficacy at 24 weeks in heavily treatment-experienced patients with HIV/AIDs.
Data from a 24-week interim analysis of two phase IIB randomized trials of TMC114 boosted with ritonavir in patients with experience of at least three classes of antiretrovirals and one or more primary PI mutations resulted in a higher mean reduction in plasma HIV RNA in the highest dose group compared with the control group.
In a press release Friday, Tibotec said the 24-week interim analysis was performed after 150 patients had reached 24 weeks in each of the two studies.
A total of 497 patients were included in the analysis.
After 24 weeks, the percentage of patients reaching undetectable virus levels ranged from 30% to 47%, compared with 10% in the control group.
The studies will continue to 96 weeks.